{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:02:31Z","timestamp":1784815351851,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.taap.2026.117804","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:44:05Z","timestamp":1774583045000},"page":"117804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Camizestrant-induced heart rate reduction is mediated via a sinoatrial node pacemaker channel mechanism"],"prefix":"10.1016","volume":"511","author":[{"given":"Andrew","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efd","family":"El-Haou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada C.","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Purbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Hawthorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Canzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Bucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Pointon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Protze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Baruscotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2026.117804_bb0005","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-5135","volume":"82","author":"Andr\u00e9","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2026.117804_bb0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/CCO.0000000000001085","article-title":"Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives","volume":"36","author":"Ascione","year":"2024","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.taap.2026.117804_bb0015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/cts.13491","article-title":"Concentration QTc analysis of giredestrant: overcoming QT\/heart rate confounding in the presence of drug-induced heart rate changes","volume":"16","author":"Brooks","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.taap.2026.117804_bb0020","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1113\/jphysiol.2005.100776","article-title":"Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels","volume":"572","author":"Bucchi","year":"2006","journal-title":"J. Physiol."},{"key":"10.1016\/j.taap.2026.117804_bb0025","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a034173","article-title":"Vagus nerve stimulation and the cardiovascular system","volume":"10","author":"Capilupi","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.taap.2026.117804_bb0030","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1038\/ncomms4775","article-title":"Exercise training reduces resting heart rate via downregulation of the funny channel HCN4","volume":"5","author":"D'Souza","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.taap.2026.117804_bb0035","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.117.311607","article-title":"Targeting miR-423-5p reverses exercise training-induced HCN4 channel remodeling and sinus bradycardia","volume":"121","author":"D'Souza","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2026.117804_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176424","article-title":"Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer","volume":"969","author":"Guglielmi","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2026.117804_bb0045","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann. Oncol."},{"issue":"16.Suppl","key":"10.1016\/j.taap.2026.117804_bb0050","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2024.42.16_suppl.1015","article-title":"H3B-6545 in women with locally advanced\/metastatic estrogen receptor-positive (ER+), HER2 negative (\u2013) breast cancer (BC)","volume":"42","author":"Hamilton","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2026.117804_bb0055","doi-asserted-by":"crossref","DOI":"10.1080\/14796694.2025.2459548","article-title":"CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+\/HER2\u2013 early breast cancer","author":"Hamilton","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.taap.2026.117804_bb0060","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00424-022-02698-4","article-title":"Paradigm shift: new concepts for HCN4 function in cardiac pacemaking","volume":"474","author":"Hennis","year":"2022","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.taap.2026.117804_bb0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-23-1796","article-title":"Phase Ia\/b study of giredestrant \u00b1 palbociclib and \u00b1 luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced\/metastatic breast cancer","volume":"30","author":"Jhaveri","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2026.117804_bb0070","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2026.117804_bb0075","series-title":"Physiology, Sinoatrial Node, StatPearls [Internet]","author":"Kashou","year":"2022"},{"key":"10.1016\/j.taap.2026.117804_bb0080","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4\/6 inhibitor resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2026.117804_bb0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yjmcc.2020.08.005","article-title":"Contribution of estrogen to the pregnancy-induced increase in cardiac automaticity","volume":"147","author":"Long","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.taap.2026.117804_bb0090","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/01.CIR.98.14.1394","article-title":"Central vagotonic effects of atropine modulate spectral oscillations of sympathetic nerve activity","volume":"98","author":"Montano","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2026.117804_bb0095","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/JCO.2022.40.16_suppl.1032","article-title":"SERENA-1: updated analyses from a phase 1 study (parts C\/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer (abstr)","volume":"40","author":"Oliveira","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2026.117804_bb0100","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.taap.2026.117804_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nbt.3745","article-title":"Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker","volume":"35","author":"Protze","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.taap.2026.117804_bb0110","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/01.RES.85.1.e1","article-title":"Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues","volume":"85","author":"Shi","year":"1999","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2026.117804_bb0115","doi-asserted-by":"crossref","first-page":"H469","DOI":"10.1152\/ajpheart.00507.2016","article-title":"The role of sympathetic and vagal cardiac control on complexity of heart rate dynamics","volume":"312","author":"Silva","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.taap.2026.117804_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.662410","article-title":"Electrophysiological and molecular mechanisms of sinoatrial node mechanosensitivity","volume":"8","author":"Turner","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.taap.2026.117804_bb0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/fon-2022-1196","article-title":"Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment","volume":"19","author":"Turner","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.taap.2026.117804_bb0130","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P3-07-28","article-title":"Abstract P3-07-28: SERENA-1: updated analyses from a phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer (abstr)","volume":"83","author":"Turner","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2026.117804_bb0135","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO3-19-09","volume":"84","author":"Vaklavas","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2026.117804_bb0140","first-page":"1","article-title":"Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity","volume":"3","author":"Zhang","year":"2017","journal-title":"Cardiooncology"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:17:24Z","timestamp":1784812644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X26001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S0041008X26001006"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2026.117804","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Camizestrant-induced heart rate reduction is mediated via a sinoatrial node pacemaker channel mechanism","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2026.117804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117804"}}